http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007065497-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a6fa364fdad27623ef890dda9062e473 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-063 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 |
| filingDate | 2005-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b133ef806de464ee957de58ebe7d5685 |
| publicationDate | 2007-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2007065497-A1 |
| titleOfInvention | Combination and method using EDTA combined with glutathione in the reduced state encapsulated in a liposome to facilitate the method of delivery of the combination as an oral, topical, intraoral or transmucosal, for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacy |
| abstract | The invention is for the combination of EDTA and glutathione in the reduced state encapsulated in a liposome for prevention and therapy of coronary artery disease (CAD), and anti-thrombotic effect and for the effect of restoring platelet aggregation, an integral component of thrombus formation, to normal. The combination is particularly efficacious for vascular deficiency ailments including atherosclerotic vascular disease, reduction of ischemic cerebral event, complications from surgical procedures including re-stenosis, neurodegenerative disease, erectile dysfunction, and vascular deficiency resulting from etiology of sepsis and chronic infection and diabetes. Additionally the invention is used as an adjunct in the management of diabetes for both the slowing and amelioration of the atherosclerotic state and as an adjunct with standard diabetic medications such as insulin for the lowering of glucose levels. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9034383-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8722093-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010096231-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010215752-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9901611-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102292088-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102292088-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010166846-A1 |
| priorityDate | 2005-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 115.